FDA Advisory No.2024-0543 || ON-BOARDING OF THE LICENSING PROCEDURES FOR HOUSEHOLD/URBAN HAZARDOUS SUBSTANCES (HUHS) ESTABLISHMENTS ON THE FOOD AND DRUG ADMINISTRATION (FDA) ESERVICES PORTAL SYSTEM
The Food and Drug Administration (FDA) continues its digital system enhancement through the development of online application platforms, particularly, the FDA eServices Portal System. These enhancements aim to further simplify […]
FDA Advisory No.2024-0542 || Resumption of the Conduct of Foreign GMP Inspection
Following the declaration of the World Health Organization (WHO), stating that COVID-19 no longer constitutes a public health emergency of international concern, and the lifting of the State of Public […]
FDA Advisory No.2024-0541 || Public Health Warning Against False Endorsement of FDA and Misleading Social Media Endorsements
The Food and Drug Administration (FDA) warns the public regarding false endorsements of health products through social media platforms. The FDA reiterates that its officials and employees are without any […]
FDA Advisory No.2024-0540 || Releasing of Food and Drug Administration Authorization at the Information and Communication Technology Management Division (ICTMD)-Records Section-Releasing Unit (RS-RU).
Releasing of Food and Drug Administration (FDA) approved authorizations and documents at the Records Section – Releasing Unit is essential for transparency and public awareness. In response to the growing […]
FDA Advisory No.2024-0498 || Delisting of COVID-19 Medicines and Devices from the List of VAT-Exempt Health Products
Republic Act (RA) No. 11534 known as the “Corporate Recovery and Tax Incentives for Enterprises (CREATE) Act” provided Value-Added Tax (VAT) Exemption to certain health products including, Drugs for Hypertension, […]
FDA Advisory No.2024-0473 || Suspension of Customer Relation Management Information System (CRMIS) starting 01 March 2024
The Food and Drug Administration hereby notifies the general public of the suspension of the FDA Customer Relation Management Information System (FDA-CRMIS) which was implemented through the issuance of FDA […]
FDA Advisory No.2024-0329 || Endorsement of Updates on the List of VAT-Exempt Medicines
Section 12 of Republic Act (RA) No. 11534 known as the “Corporate Recovery and Tax Incentives for Enterprises (CREATE) Act” provided Value-Added Tax (VAT) Exemption to certain health products including, […]
FDA Advisory No.2024-0320 || AD INTERIM AVAILABILITY OF OVER-THE-COUNTER (OTC) PAYMENT FOR SELECTED FDA APPLICATIONS/ TRANSACTIONS
In the interest of effective delivery of public service, the Food and Drug Administration (FDA) would like to inform all FDA stakeholders of the availability of Over-the-Counter (OTC) Payment System […]
Joint Advisory of DA-BFAR and FDA || All Exporters of Fish and Fishery/ Aquatic Products and Processed Meat and Meat Products to Kingdom of Saudi Arabia
https://www.sfda.gov.sa/en/forms/79005 Attachments JOINT ADVISORY OF DA-BFAR AND FDA (373 kB)
FDA Advisory No.2024-0006 || Endorsement of Updates on the List of VAT-Exempt Health Products
Section 12 of Republic Act (RA) No. 11534 known as the “Corporate Recovery and Tax Incentives for Enterprises (CREATE) Act” provided Value-Added Tax (VAT) Exemption to certain health products including, […]